CA3215906A1 - Use of an orexin 2 receptor agonist for post operation recovery - Google Patents
Use of an orexin 2 receptor agonist for post operation recovery Download PDFInfo
- Publication number
- CA3215906A1 CA3215906A1 CA3215906A CA3215906A CA3215906A1 CA 3215906 A1 CA3215906 A1 CA 3215906A1 CA 3215906 A CA3215906 A CA 3215906A CA 3215906 A CA3215906 A CA 3215906A CA 3215906 A1 CA3215906 A1 CA 3215906A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- subject
- methyl
- administration
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163170211P | 2021-04-02 | 2021-04-02 | |
| US63/170,211 | 2021-04-02 | ||
| PCT/IB2022/053085 WO2022208478A1 (en) | 2021-04-02 | 2022-04-01 | Use of an orexin 2 receptor agonist for post operation recovery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3215906A1 true CA3215906A1 (en) | 2022-10-06 |
Family
ID=81326367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3215906A Pending CA3215906A1 (en) | 2021-04-02 | 2022-04-01 | Use of an orexin 2 receptor agonist for post operation recovery |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240165092A1 (https=) |
| EP (1) | EP4313045A1 (https=) |
| JP (1) | JP2024511676A (https=) |
| KR (1) | KR20230165782A (https=) |
| CN (1) | CN117396203A (https=) |
| AU (1) | AU2022252108A1 (https=) |
| BR (1) | BR112023020104A2 (https=) |
| CA (1) | CA3215906A1 (https=) |
| CO (1) | CO2023013001A2 (https=) |
| MX (1) | MX2023011669A (https=) |
| TW (1) | TW202304437A (https=) |
| WO (1) | WO2022208478A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202502342A (zh) * | 2023-06-02 | 2025-01-16 | 日商武田藥品工業股份有限公司 | 食慾素２受體促效劑用於改善睡眠期間之呼吸功能的用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5854204A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals, Inc. | Aβ peptides that modulate β-amyloid aggregation |
| JP2001500852A (ja) | 1996-08-27 | 2001-01-23 | プレーシス ファーマスーティカルズ インコーポレイテッド | Ｄ―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター |
| PL3411358T3 (pl) * | 2016-02-04 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Podstawiony związek piperydynowy i jego zastosowanie |
| US11034700B2 (en) | 2017-03-08 | 2021-06-15 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
| WO2018164191A1 (ja) | 2017-03-08 | 2018-09-13 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| US11319286B2 (en) | 2017-08-03 | 2022-05-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| US20200207734A1 (en) | 2017-08-03 | 2020-07-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| US12077522B2 (en) | 2018-06-29 | 2024-09-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| JP7413261B2 (ja) | 2018-06-29 | 2024-01-15 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| EP3896060B1 (en) | 2018-12-12 | 2023-08-16 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP7379374B2 (ja) | 2018-12-12 | 2023-11-14 | 武田薬品工業株式会社 | 複素環化合物 |
| SG11202106791XA (en) | 2019-01-31 | 2021-07-29 | Takeda Pharmaceuticals Co | Heterocyclic compound and use thereof |
| US11098029B2 (en) | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
| WO2020167701A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | Pyrrolidine orexin receptor agonists |
| WO2021026047A1 (en) | 2019-08-08 | 2021-02-11 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| CA3154321A1 (en) * | 2019-09-13 | 2021-03-18 | Takeda Pharmaceutical Company Limited | Tak-925 for use in treating narcolepsy |
-
2022
- 2022-04-01 BR BR112023020104A patent/BR112023020104A2/pt unknown
- 2022-04-01 CN CN202280037124.XA patent/CN117396203A/zh active Pending
- 2022-04-01 US US18/553,348 patent/US20240165092A1/en active Pending
- 2022-04-01 CA CA3215906A patent/CA3215906A1/en active Pending
- 2022-04-01 TW TW111112864A patent/TW202304437A/zh unknown
- 2022-04-01 AU AU2022252108A patent/AU2022252108A1/en active Pending
- 2022-04-01 WO PCT/IB2022/053085 patent/WO2022208478A1/en not_active Ceased
- 2022-04-01 EP EP22715747.6A patent/EP4313045A1/en active Pending
- 2022-04-01 KR KR1020237033928A patent/KR20230165782A/ko active Pending
- 2022-04-01 MX MX2023011669A patent/MX2023011669A/es unknown
- 2022-04-01 JP JP2023560767A patent/JP2024511676A/ja active Pending
-
2023
- 2023-09-29 CO CONC2023/0013001A patent/CO2023013001A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022208478A1 (en) | 2022-10-06 |
| KR20230165782A (ko) | 2023-12-05 |
| CO2023013001A2 (es) | 2023-10-30 |
| CN117396203A (zh) | 2024-01-12 |
| US20240165092A1 (en) | 2024-05-23 |
| JP2024511676A (ja) | 2024-03-14 |
| AU2022252108A1 (en) | 2023-10-05 |
| BR112023020104A2 (pt) | 2023-11-14 |
| MX2023011669A (es) | 2023-10-18 |
| TW202304437A (zh) | 2023-02-01 |
| EP4313045A1 (en) | 2024-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025016462A (ja) | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター | |
| US12558327B2 (en) | Methods and compositions for treating sleep apnea | |
| WO2021048821A1 (en) | Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness | |
| US20080175903A1 (en) | Treatment of anxiety with eszopiclone | |
| US20090275562A1 (en) | Tolerability of mirtazapine and a second active by using them in combination | |
| RU2011146032A (ru) | Соединения-агонисты рецептора 5-ht4 для лечения расстройств познавательной способности | |
| IL322430A (en) | 5-MEO-DMT for use in the treatment of postpartum depression | |
| EP3400940B1 (en) | Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium | |
| CA3215906A1 (en) | Use of an orexin 2 receptor agonist for post operation recovery | |
| JP5042625B2 (ja) | 抗炎症剤として有用なα−アミノアミド誘導体 | |
| KR102266696B1 (ko) | 주의력 및 인지 장애, 및 신경 퇴행성 장애와 관련된 치매 치료용 신규 치료제 | |
| WO2022004788A1 (ja) | 代謝異常を伴う疾患又は症候群における筋力低下症状の改善剤又は予防剤 | |
| WO2022190060A1 (en) | An orexin 2 receptor agonist for the treatment of an orexin-mediated disease or disorder | |
| JP2023520455A (ja) | 睡眠時無呼吸を治療するための方法および組成物 | |
| CN111670041A (zh) | 用在组合疗法(睡眠障碍或中枢神经系统障碍)中的nmda受体调节剂(拉帕斯汀)组合 | |
| US20060217394A1 (en) | Treatment of anhedonia | |
| KR20250057804A (ko) | 수면 무호흡증을 치료하기 위한 방법 및 조성물 | |
| BR122024024457A2 (pt) | Usos e composições para tratamento da apneia do sono e kit relacionado | |
| EP4719397A1 (en) | Use of an orexin 2 receptor agonist for improving respiratory function during sleep | |
| HK40000275B (en) | Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium | |
| TW201517903A (zh) | 便秘症之預防或治療藥 | |
| Yang et al. | Sedative Hypnotic and Anesthetic Agents: Their Effect on the Heart |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250320 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250320 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250320 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260319 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260319 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260331 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260331 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260331 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260402 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260402 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260402 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260402 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260402 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260402 |